NCT02370043View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-Effect of KQ-791

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

July 31, 2015

Study Completion Date

July 31, 2015

Conditions
Healthy VolunteersInsulin Resistance
Interventions
DRUG

KQ-791

Capsules administered orally while fasting, in up to 3 periods

DRUG

KQ-791 (after meal)

Single dose of KQ-791 in capsules, after a meal, in 1 period

DRUG

Placebo

Capsules, administered orally, in 1 period

Trial Locations (2)

H3X 2Hp

Inventiv, Montreal

G1P 0A2

inVentiv, Québec

Sponsors
All Listed Sponsors
lead

Kaneq Bioscience Limited

OTHER